Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERWake Forest University Health Sciences Winston-Salem, NC 27157
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTESOriginal contains colored plates: ALL DTIC reproductions will be in black and white.
ABSTRACTThe overall goal of this project s to understand the anti-tumor effects of FAS inhibitors. We have followed up on our previous findings by further evaluating the role of ER stress in tumor cells treated with FAS inhibitors. Our results suggest that ER stress may initiate the cell death program when FAS is inhibited in prostate tumor cell lines. Moreover, the data also suggest that the ER may sense fatty acid levels in tumor cells. A further connection to ER stress was discovered by showing that other ER stressing agents like Velcade induce fatty acid synthase activity and sensitize cells to the effects of FAS inhibitors. We have also made the novel observation that FAS expression is regulated by the src oncogene and that FAS inhibitors can block src driven matrigel invasion. Combined these data provide insight into how disruption of the FAS axis can be further exploited to inhibit prostate tumor growth and metastases. We have also extended our previous crystallography studies by solving the crystal structure of FAS bound to a cleaved orlistat. These data will provide valuable insight into future drug discovery and design within the FAS pathway. In total, we have made great strides toward understanding the anti-tumor effects of orlistat and other FAS inhibitors in prostate cancer through a multi-disciplinary approach combining cell biology, biochemistry and crystallography.
SUBJECT TERMS
A. IntroductionThis is the annual report for grant # W81XWH-05-1-0065 entitled "Inhibition of Fatty Acid Synthase by Orlistat: A Novel Therapeutic". The funding period fo...